Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $1.24 billion. The enterprise value is $950.74 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 48.86 million shares outstanding. The number of shares has increased by 72.23% in one year.
| Current Share Class | 48.86M |
| Shares Outstanding | 48.86M |
| Shares Change (YoY) | +72.23% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 5.54% |
| Owned by Institutions (%) | 59.25% |
| Float | 26.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.17 |
| P/TBV Ratio | 4.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.44, with a Debt / Equity ratio of 0.00.
| Current Ratio | 17.44 |
| Quick Ratio | 17.14 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.98% and return on invested capital (ROIC) is -22.50%.
| Return on Equity (ROE) | -30.98% |
| Return on Assets (ROA) | -21.37% |
| Return on Capital (ROIC) | -22.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.85M |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ELVN has paid $232,000 in taxes.
| Income Tax | 232,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +144.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +144.52% |
| 50-Day Moving Average | 26.42 |
| 200-Day Moving Average | 22.02 |
| Relative Strength Index (RSI) | 41.11 |
| Average Volume (20 Days) | 244,820 |
Short Selling Information
The latest short interest is 6.91 million, so 14.14% of the outstanding shares have been sold short.
| Short Interest | 6.91M |
| Short Previous Month | 6.51M |
| Short % of Shares Out | 14.14% |
| Short % of Float | 26.09% |
| Short Ratio (days to cover) | 21.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -99.09M |
| Pretax Income | -79.60M |
| Net Income | -85.21M |
| EBITDA | -98.77M |
| EBIT | -99.09M |
| Earnings Per Share (EPS) | -$1.90 |
Full Income StatementBalance Sheet
The company has $291.83 million in cash and $85,000 in debt, giving a net cash position of $291.75 million or $5.97 per share.
| Cash & Cash Equivalents | 291.83M |
| Total Debt | 85,000 |
| Net Cash | 291.75M |
| Net Cash Per Share | $5.97 |
| Equity (Book Value) | 288.40M |
| Book Value Per Share | 6.10 |
| Working Capital | 279.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$68.47 million and capital expenditures -$58,000, giving a free cash flow of -$68.53 million.
| Operating Cash Flow | -68.47M |
| Capital Expenditures | -58,000 |
| Free Cash Flow | -68.53M |
| FCF Per Share | -$1.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |